1258 related articles for article (PubMed ID: 27139057)
1. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer.
Kim E; Kim K; Kyu Chie E; Oh DY; Tae Kim Y
J BUON; 2017; 22(4):1046-1052. PubMed ID: 28952226
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W;
J Clin Oncol; 2007 May; 25(15):1960-6. PubMed ID: 17452677
[TBL] [Abstract][Full Text] [Related]
8. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
9. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Herman JM; Wild AT; Wang H; Tran PT; Chang KJ; Taylor GE; Donehower RC; Pawlik TM; Ziegler MA; Cai H; Savage DT; Canto MI; Klapman J; Reid T; Shah RJ; Hoffe SE; Rosemurgy A; Wolfgang CL; Laheru DA
J Clin Oncol; 2013 Mar; 31(7):886-94. PubMed ID: 23341531
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
[TBL] [Abstract][Full Text] [Related]
17. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Karasic TB; O'Hara MH; Loaiza-Bonilla A; Reiss KA; Teitelbaum UR; Borazanci E; De Jesus-Acosta A; Redlinger C; Burrell JA; Laheru DA; Von Hoff DD; Amaravadi RK; Drebin JA; O'Dwyer PJ
JAMA Oncol; 2019 Jul; 5(7):993-998. PubMed ID: 31120501
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
